Medical devices for collecting pathogenic cells
View Patent ↗Disclosed is a medical device constructed and arranged for contact with a flow of blood or other bodily fluid of a patient and including an attached binding agent or a roughened surface that binds to pathogenic cells targeted for elimination from the blood or other bodily fluid. Also disclosed are methods for making and using the device.
1. A method for destroying pathogenic cells of a patient, comprising:
applying a pathogenic cell destroying agent to pathogenic cells localized to a device exposed to a flow of a bodily fluid of the patient, the device having a binding agent attached thereto through a self-assembled molecular monolayer and to which the pathogenic cells are bound or having a roughened surface to which the pathogenic cells are bound, wherein the binding agent comprises an antibody or a ligand that binds specifically to a cell surface protein of the pathogenic cells.
2. The method of claim 1 , wherein the bodily fluid is blood, and wherein device has portions that engage a blood vessel wall inside a blood vessel lumen of the patient.
3. The method of claim 1 , wherein the device comprises a vascular implant selected from the group consisting of: a vascular filter, a catheter, a wire guide, a stent, a coil, circulating particles, a needle, a graft, and a balloon.
4. The method of claim 1 , wherein the device has said binding agent attached thereto through a self-assembled molecular monolayer and to which the pathogenic cells are bound.
5. The method of claim 1 , wherein the device comprises a coating comprising an active agent other than the binding agent and wherein the active agent is selected from: chemotherapeutic agents, radiation sensitizing agents, radioprotective agents, anti-restenosis agents, anti-inflammatory agents, antiproliferative agents, pro-healing agents, gene therapy agents, extracellular matrix modulators, anti-thrombotic agents, anti-platelet agents, antiangioplastic agents, antisense agents, anticoagulants, antibiotics, bone morphogenetic proteins, integrins, disintegrins, smooth muscle cell inhibitors, immunosuppressive agents, and anti-antigenic agents.
6. The method of claim 1 , wherein the self assembled molecular monolayer comprises a self assembled monolayer of phosphonic acid molecules.
7. The method of claim 1 , wherein the pathogenic cells are cancer cells.
8. A medical device, comprising:
an implant constructed and arranged to be placed within a vessel lumen of a patient;
a surface to which pathogenic cells circulating in bodily fluid of the patient bind to non-pathogenic cells circulating in bodily fluid of the patient, wherein the surface includes a binding agent attached to the implant through a self-assembled molecular monolayer and which binds to pathogenic cells circulating in bodily fluid of the patient, or wherein the surface is a pathogenic cell binding roughened surface; and
wherein the binding agent is an antibody or a ligand that binds specifically to a protein on the pathogenic cells.
9. The medical device of claim 8 , wherein the implant comprises a frame constructed and arranged to engage a blood vessel wall defining a blood vessel lumen of a patient to secure the position of the implant.
10. The medical device of claim 8 , wherein the surface includes said binding agent attached to the implant through a self-assembled molecular monolayer.
11. The medical device of claim 10 , wherein the pathogenic cells are cancer cells.
12. The medical device of claim 11 , wherein the protein is a cell surface protein.
13. The medical device of claim 8 , wherein the binding agent binds specifically to the pathogenic cells.
14. The method of claim 1 , comprising said binding agent attached to the device through a self-assembled molecular monolayer and to which the pathogenic cells are bound, and wherein said binding agent comprises a linker.
15. The method of claim 14 , wherein the binding agent is an antibody or ligand that binds to MMP-1, MMP-3, MMP-4, MMP-5, MMP-9, MMP-11, VEGFR3, CCR7, CXCR5, CXCR4, Nrp-2, EphA2, HER2, CD96, CD33, CD20, ZAP-70, CD38, CD5, CD23, CD19, CD40, CD45 CD45A, CD21, CD52, CALLA, Tdt, B-lymphocyte stimulator, VEGF, EGFR, SDF protein, Ber-EP4, or CK20.
16. The method of claim 15 , wherein the binding agent is an antibody or ligand that binds to EGFR.
17. The method of claim 16 , wherein the binding agent is an antibody that binds to EGFR.
18. The method of claim 1 , wherein the pathogenic cell destroying agent comprises radiation.
19. The method of claim 18 , wherein the radiation is applied from one or more sources external to the patient.
20. The method of claim 18 , wherein the radiation is applied intravascularly.
21. The method of claim 2 , where only the portions of the device which are not in contact with the vessel wall are coated with said binding agent.